

## Formulary changes effective Oct. 1, 2013

BWC plans to amend coverage in three classes of drugs and update the prior authorization requirements for an additional 88 drug classes.

1. Limit reimbursement for sedative hypnotic agents to the following medications: zolpidem IR & CR tablets (Ambien®), Eszopiclone (Lunesta®), Temazepam (Restoril®), Zaleplon (Sonata®).
2. Remove the following sleep aid agents from the formulary: Chloral Hydrate, Halcion®, Dalmane®, Prosom® Doral®, Rozerem®, Edular®, Silenor®, Zolpimist®.  
**Note:** These changes will not apply to injured workers currently receiving regular prescriptions for any of the medications removed from the formulary.
3. Limit the maximum daily dose to be reimbursed for anti-anxiety drugs in the benzodiazepine class to the equivalent of 40 mg of diazepam (Valium®).  
**Note:** This change will not apply to injured workers currently receiving regular prescriptions for anti-anxiety medications above the maximum daily dose limit.
4. Limit reimbursement for the drug Metaxalone (Skelaxin®) to only those cases in which the injured worker has tried one other formulary skeletal muscle relaxant for at least 14 days and has experienced a therapeutic failure, demonstrated unacceptable side effects or systemic allergic reaction (as defined in OAC 4123-6-21 paragraphs (J)(1) and (J)(2)). The skeletal muscle relaxant drug class formulary restriction of 90 days of coverage plus one additional 30 days of coverage with prior authorization still applies to Metaxalone.
5. Allow reimbursement for transdermal forms of the drugs Fentanyl and Buprenorphine (Butrans®) as first tier sustained release opiates in claims with clinical documentation of an inability to swallow or absorb oral medications. Reimbursement will also be allowed for either transdermal agent in claims with documentation of a therapeutic failure, demonstrated unacceptable side effects or systemic allergic reaction (as defined in OAC 4123-6-21 paragraphs (J)(1) and (J)(2)) to an oral sustained release opiate. Reimbursement for Butrans® is limited to claims requiring a daily morphine equivalent dose of 90 mg or less per day. Reimbursement for all sustained release opiate medications is limited to use of a single sustained release agent at any one time.
6. Add the drug Vilazodone (Viibryd®) to the serotonin reuptake inhibitor class of anti-depressants.
7. Approved forms of sustained release gabapentin and gabapentin encarbil will be eligible for reimbursement following a 30-day trial of immediate or sustained release gabapentin that results in a documented clinical failure, as defined in OAC 4123-6-21(J)(2). Reimbursement shall be restricted to a single form of gabapentin at any one time.

Questions about the formulary or BWC's Pharmacy Program can be directed to Program Director John Hanna at [Johnnie.H.12@bwc.state.oh.us](mailto:Johnnie.H.12@bwc.state.oh.us).